SCHEDULE: BlackRock Discloses 6.4% Stake in Nuvation Bio Inc.

BlackRock, Inc. has reported a 6.4% beneficial ownership stake in Nuvation Bio Inc., holding over 21.7 million shares of common stock.

Summary

• BlackRock, Inc. filed a Schedule 13G, disclosing its beneficial ownership in Nuvation Bio Inc.
• As of June 30, 2025, BlackRock beneficially owns an aggregate of 21,708,843 shares of Nuvation Bio Inc. common stock.
• This ownership represents 6.4% of the total outstanding common stock of Nuvation Bio Inc.
• BlackRock holds sole voting power over 21,153,392 shares and sole dispositive power over 21,708,843 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Nuvation Bio Inc.
• BlackRock Investment Management, LLC is identified as a subsidiary that may beneficially own 5% or greater of the outstanding shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing (Schedule 13G) reporting beneficial ownership and does not contain information that would inherently convey positive or negative sentiment about the issuer's performance or outlook.

Positives

• BlackRock, a major institutional investor, holds a significant 6.4% stake in Nuvation Bio Inc., which can be interpreted as a signal of institutional confidence.
• The filing confirms that BlackRock's acquisition and holding of shares are in the ordinary course of business and not for control purposes, indicating a passive investment strategy.

Future Outlook

This Schedule 13G filing does not provide any forward-looking statements or guidance regarding Nuvation Bio Inc.'s future operations, financial performance, or strategic plans. It is solely a disclosure of current beneficial ownership.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing is a routine disclosure required by the SEC when an institutional investor acquires more than 5% beneficial ownership in a public company. It indicates that a major asset manager, BlackRock, has taken a significant passive stake in Nuvation Bio Inc., which is common for large investment firms managing diversified portfolios. Such filings provide transparency into institutional holdings, which can be a factor in market sentiment and liquidity for the issuer's stock.

Stakeholder Impact

• Shareholders: The disclosure of BlackRock's significant 6.4% stake may be viewed positively by other shareholders as it indicates a major institutional investor's confidence in Nuvation Bio Inc., potentially enhancing market liquidity and stability.
• Management: Nuvation Bio Inc. management gains transparency into a significant institutional holder, which can influence investor relations strategies.

Key Dates

Keywords

Nuvation Bio Inc., BlackRock, Schedule 13G, beneficial ownership, common stock, institutional investor, SEC filing, equity stake